There are 398 resources available
37P - SLC22A17 as a Novel Therapeutic Target for Triple-Negative Breast Cancer
Presenter: Ajaikumar Kunnumakkara
Session: Poster Display session
38P - Tumour infiltrating lymphocytes and correlation with prognostic signature scores in early-stage hormone-positive, HER2-negative (ER+/HER2-) breast cancer.
Presenter: Mairi Lucas
Session: Poster Display session
39P - Understanding the crosstalk between micro-RNA and Wnt signaling cascade associated with the expression level of HOXB13 and SRC genes in female breast cancer.
Presenter: Aiza Khan
Session: Poster Display session
40P - Connexin43 as double therapeutic target in triple negative breast cancer: role in tumour progression and antitumour immune response
Presenter: Marina Rodriguez-Candela Mateos
Session: Poster Display session
41P - The impact of tumour infiltrating lymphocyte subpopulations on pathological complete response in HER2+ breast cancer
Presenter: Camille Hurley
Session: Poster Display session
42P - Endothelin-1 genetic polymorphism (SNP rs5370-TT) fails to predict resistance to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial
Presenter: Simon Peter Gampenrieder
Session: Poster Display session
43P - Dynamic alterations of immunosenescence-related genes in older women with breast cancer receiving chemotherapy
Presenter: Qi Wu
Session: Poster Display session
44P - Breast cancer subtypes in Georgia: Higher frequency of triple-negative breast cancer compared to resource-rich areas
Presenter: Ivane Kiladze
Session: Poster Display session
45P - Spatially-resolved single-cell HER2 tumor heterogeneity captured by biophysical modeling
Presenter: Daniel Cook
Session: Poster Display session
46P - Co-expression of GR with PR isoforms is associated with differential prognosis in estrogen receptor positive breast cancer
Presenter: Vidya Nimbalkar
Session: Poster Display session